Valneva And Serum Institute Mutually Terminate Chikungunya Vaccine License; Valneva Regains Full Control To Accelerate Access In High-Risk Countries

Valneva SE ("Valneva" or "the Company"), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company today announced that they have mutually agreed to discontinue their license agreement for Valneva's single-shot chikungunya vaccine.

Valneva´s strategic intent in regaining full rights is to assume direct control over its supply chain and commercialization for endemic high-risk countries, thereby accelerating access for regions most affected by the disease. 

Supporting access to the vaccine in low-and-middle-income countries (LMICs) falls within the framework of the funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2024 with co-funding from the European Union1.